Table 3.
Drug screening assays
| Agent | % inhibition (log p value) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| OV469 | OV778 | OV798a | OV817a | OV820a | OV840a | OV899b | OV860b | OV867 | OV870 | |
| 40.39 | 56.46 | 34.49 | 20.72 | 18.65 | 31.10 | 36.24 | 22.00 | 30.25 | 18.4 | |
| Olaparib | (−2.82) | (−1.73) | (−1.53) | (−4.67) | (−3.11) | (−1.58) | (−1.78) | (−1.62) | (−2.72) | (−3.15) |
| Paclitaxel | 46.29 | 17.69 | 66.95 | 61.61 | 62.39 | 81.89 | 0.28 | 22.95 | 29.88 | 21.91 |
| (−1.84) | (−0.39) | (−2.83) | (−6.38) | (−5.09) | (−4.35) | (−0.02) | (−1.33) | (−1.99) | (−2.59) | |
| 46.01 | −45.02 | 41.4 | 20.84 | 92.84 | 66.31 | 36.89 | 51.05 | 3.57 | 12.39 | |
| Mocetinostat | (−1.85) | (−1.09) | (−1.22) | (−3.39) | (−6.35) | (−2.88) | (−2.75) | (−3.32) | (−0.45) | (−3.35) |
| 37.81 | −91.96 | −66.94 | 9.18 | 44.87 | −18.14 | 19.31 | 17.06 | −39.75 | 10.34 | |
| Trametinib | (−2.74) | (−1.70) | (−2.53) | (−1.07) | (−3.64) | (−0.68) | (−0.52) | (−1.82) | (−1.61) | (−1.81) |
| 50.53 | −84.45 | 74.93 | 61.12 | 78.77 | 77.77 | −7.86 | 28.48 | 28.69 | 0.37 | |
| LY294002 | (−2.90) | (−2.46) | (−2.14) | (−6.28) | (−5.50) | (−3.59) | (−0.65) | (−1.89) | (−1.44) | (−0.4) |
| 79.70 | −90.78 | 58.90 | 38.65 | 80.16 | 69.81 | 24.57 | 39.56 | 39.63 | 29.30 | |
| AZD5363 | (−3.88) | (−3.35) | (−1.78) | (−4.65) | (−5.21) | (−3.53) | (−1.37) | (−2.20) | (−2.79) | (−3.67) |
| 40.28 | −94.71 | −8.59 | 30.46 | −98.36 | 37.60 | 7.19 | 8.69 | 4.68 | ||
| BBI503 | (−1.26) | (−1.43) | (−0.14) | – | (−2.46) | (−2.67) | (−2.66) | (−0.21) | (−0.67) | (−1.07) |
| 80.59 | 3.57 | 90.32 | 94.77 | 98.21 | 91.43 | 65.79 | 57.97 | 63.51 | 75.15 | |
| MK-1775 | (−3.81) | (−0.07) | (−2.42) | (−7.00) | (−5.78) | (−4.18) | (−4.29) | (−3.75) | (−3.90) | (−6.19) |
| 85.34 | 33.00 | −32.89 | 99.11 | 97.71 | −10.31 | 99.89 | 17.32 | 3.95 | 98.99 | |
| Sorafenib | (−4.31) | (−1.16) | (−0.62) | (−7.21) | (−5.78) | (−0.30) | (−5.16) | (−1.01) | (−0.20) | (−6.84) |
| 99.98 | 99.78 | 99.96 | 99.98 | 99.99 | 99.96 | 98.2 | 99.9 | 99.90 | 99.98 | |
| APR-246 | (−4.54) | (−3.65) | (−2.74) | (−7.21) | (−5.84) | (−4.26) | (−6.35) | (−5.14) | (−4.70) | (−6.82) |
| 99.97 | 99.38 | 99.94 | 99.98 | 99.96 | 99.91 | 95.39 | 92.57 | 97.95 | 99.79 | |
| CB-5083 | (−4.54) | (−3.66) | (−2.74) | (−7.21) | (−5.85) | (−4.27) | (−5.86) | (−5.04) | (−4.61) | (−6.83) |
| 93.29 | −60.6 | 0.73 | 30.34 | 13.02 | −99.69 | 14.06 | 75.78 | 65.93 | 25.80 | |
| Napabucasin | (−4.22) | (−1.02) | (−0.01) | (−4.39) | (−1.90) | (−1.85) | (−1.44) | (−3.86) | (−3.67) | (−4.44) |
Results are reported as % inhibition (log p value).
Clinically significant inhibition defined as >50% inhibition, displayed in bold.
a
Subject 3.
b
Subject 4.